Home Featured Page 173

Featured

Latest

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Opinions | The Psychedelic Community Takes Itself Too Seriously

Algernon Pharmaceuticals Announces Private Placement

Issues of Patient Safety and Ethical Violations in Psychedelic Therapy

Psychedelic Bulletin #115 – Mydecine Looks Set to Shutter; MindMed Gains...

PT348 – Steve DeAngelo – Cannabis and Psychedelics: Industry, Consciousness, Justice,...

HAVN Life Announces the close of the first tranche of its...

Bright Minds Biosciences Comments on Recent Trading Activity

Small Pharma Announces TSXV Approval of Normal Course Issuer Bid

FILAMENT HEALTH ANNOUNCES EIGHTH PATENT ISSUANCE

Reunion Neuroscience Inc. to Commence Trading on the Toronto Stock Exchange...

EDITOR PICKS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Who Gets to Heal?

Opinions | The Psychedelic Community Takes Itself Too Seriously

Algernon Pharmaceuticals Announces Private Placement

Issues of Patient Safety and Ethical Violations in Psychedelic Therapy

Psychedelic Bulletin #115 – Mydecine Looks Set to Shutter; MindMed Gains...

PT348 – Steve DeAngelo – Cannabis and Psychedelics: Industry, Consciousness, Justice,...

HAVN Life Announces the close of the first tranche of its...

Bright Minds Biosciences Comments on Recent Trading Activity

Small Pharma Announces TSXV Approval of Normal Course Issuer Bid

FILAMENT HEALTH ANNOUNCES EIGHTH PATENT ISSUANCE

Reunion Neuroscience Inc. to Commence Trading on the Toronto Stock Exchange...

EDITOR PICKS

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY